Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Expected outcomes of therapy

8 evidence topics · 7 sources

Summary

In the NATIVE trial at week 24, in the full analysis population with missing data handled by multiple imputation, a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) occurred in 55% of participants receiving lanifibranor 1200 mg (significant) and 48% receiving 800 mg (not significant), compared with 33% receiving placebo; resolution of NASH without worsening of fibrosis occurred in 49%, 39%, and 22%. The company topline release reported the primary end point in the ITT population as 49% (1200 mg, P=0.004), 41% (800 mg, P=0.061), and 27% (placebo). The trial publication states that fibrosis is the primary predictor of complications and death in NASH and that regression of fibrosis is associated with decreased risk of liver-related events.

Evidence linking fibrosis stage to outcomes comes from pooled cohort studies and models. Across cohort studies of biopsy-proven NAFLD, stage 3 to 4 fibrosis carried higher all-cause (HR 3.32) and liver-related mortality (HR 10.40) than stage 0 to 2. The estimated time to progress by one stage was 13.3 years from F2 and 22.2 years from F3, and the time to regress by one stage was 12.5 years from F3 and 20.4 years from F2. A US model estimated that a hypothetical therapy halting fibrosis progression in MASLD would reduce cases of decompensated cirrhosis by 11-39%, hepatocellular carcinoma by 10-34%, and liver-related deaths by 8-31%. The AASLD resmetirom update states that stabilization of fibrosis may portend important long-term benefits. The EASL guideline states that agents receiving accelerated approval for MASH must demonstrate beneficial effects on clinical outcomes (mortality, decompensation, liver transplantation, and hepatocellular carcinoma).